Published on : Sep 16, 2016
ALBANY, New York, September 16, 2016: ResearchMoz.us recently announced the addition of a new report, titled “Global Ophthalmology Drugs Market to 2022-Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period.” The report is intended to present a comprehensive overview of the market and provide insights into the growth drivers and restraints that are likely to influence the market through 2022.
Based on in-depth research, the report forecasts strong growth for the global ophthalmology drugs market. Between 2016 and 2022, the market is poised to surge at a CAGR of 9.48%. The global ophthalmology drugs market is expected to reach US$26 bn by the end of 2022, from a valuation of US$13.7 bn in 2015. Besides forecasting the market figures, the report also sheds light on the drugs likely to achieve the blockbuster status and the performance of key companies through the forecast period.
Ophthalmology is a therapy that deals with prevention, diagnosis, and treatment of diseases commonly associated with the visual and eye system. A majority of eye disorders occur over a long time and are initially asymptomatic. Most of them only cause a slight decrease in vision at the initial stage only to increase with time. Ophthalmologic disorders currently have no cure and the treatment is aimed at managing the diseases indication, thereby reducing the severity of symptoms and ensure slow progression.
Currently, angiogenesis inhibitors make the most effective and commonly used therapies in the treatment of ophthalmology. Although several generics are available in the market for the treatment of ophthalmology disorders, there have been many products that are attracting substantial revenues. A few of these are Eylea, Restasis, Lucentis, and Lumigan.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=799448
Despite a high degree of uncertainty within the research and development of ophthalmology drugs, the market exhibits a significant number of drugs in the pipeline, at 734. A majority of these products are novel active pharmaceutical ingredients. Only a few of these products are either repositioned from other indications or generics. The product pipeline for ophthalmology is thus diverse and large. The report presents a comparison between the consumption of the pipeline therapeutics and the existing ones in the market.
Furthermore, the report also includes a detailed analysis on the vendor landscape in the market. It profiles some of the leading players operating in the market and studies the various strategies they adopted in order to gain competitive advantage. The product portfolio of these companies are analyzed and developmental strategies they adopted are evaluated in detail. The impact of these strategies on the overall market’s trajectory is examined in the report. Besides this, the impact of the recent government laws and regulations on the overall operations is studied and evaluated in detail.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org